Replimune Group (REPL) Projected to Release Quarterly Earnings on Wednesday

Replimune Group (NASDAQ:REPL) is expected to be releasing its Q2 2027 results before the market opens on Wednesday, October 28th. Analysts expect Replimune Group to announce earnings of ($0.7840) per share and revenue of $1.00 million for the quarter. Investors may review the information on the company’s upcoming Q2 2027 earnings summary page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, analysts expect Replimune Group to post ($2.82) EPS for the current fiscal year and ($2.04) EPS for the next fiscal year.

Replimune Group Stock Up 0.5%

Shares of REPL traded up $0.07 during midday trading on Tuesday, reaching $12.54. 95,546 shares of the company were exchanged, compared to its average volume of 4,294,604. Replimune Group has a 1-year low of $1.50 and a 1-year high of $16.33. The stock has a 50-day moving average price of $13.48 and a 200-day moving average price of $9.19. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -3.97 and a beta of 0.93.

Insider Transactions at Replimune Group

In other Replimune Group news, CFO Emily Hill sold 9,256 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $14.28, for a total transaction of $132,175.68. Following the transaction, the chief financial officer owned 215,852 shares of the company’s stock, valued at $3,082,366.56. This trade represents a 4.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of Replimune Group stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $98,987.04. Following the completion of the transaction, the chief accounting officer owned 99,425 shares of the company’s stock, valued at approximately $1,289,542.25. The trade was a 7.13% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 79,124 shares of company stock valued at $1,038,364 in the last three months. Corporate insiders own 5.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Weiss Ratings downgraded Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. upped their price target on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, August 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Finally, Wolfe Research raised shares of Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.